Please visit answersincme.com/ADT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses combination locoregional and systemic therapies in advanced non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Explain the rationale for combining locoregional therapies with immunotherapies to treat advanced NSCLC; Describe the clinical implications for combining novel locoregional therapies with systemic immunotherapy for advanced NSCLC; and Outline practical strategies to optimize treatment for combination therapy in advanced NSCLC.

Please visit answersincme.com/PGS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses integrating non-steroidal mineralocorticoid receptor antagonists (MRAs) in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.

Please visit answersincme.com/DCF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in chronic kidney disease discuss the importance of early detection and optimized management by both primary care physicians and nephrologists. Upon completion of this activity, participants should be better able to: Identify the role of timely assessment and early diagnosis in optimizing outcomes in patients with chronic kidney disease (CKD); Describe approved and emerging pharmacologic treatment options for patients with CKD; and Outline patient-centered strategies to maximize patient care in CKD.

Please visit answersincme.com/ZZB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses available and emerging consolidation immunotherapies for the treatment of patients with unresectable stage III non–small-cell lung cancer (NSCLC). Upon completion of this activity, participants should be better able to: Describe the clinical impact of approved and emerging consolidation immunotherapies in patients with unresectable stage III NSCLC; Identify factors that may inform the use of guideline-recommended and emerging consolidation immunotherapies in patients with unresectable stage III NSCLC; and Recognize the clinical significance of investigational approaches to the use of consolidation immunotherapy in unresectable stage III NSCLC.

Please visit answersincme.com/BTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses recent clinical data in dual immunotherapy combinations for non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Discuss the most recent clinical data informing the efficacy and safety of chemotherapeutic regimens, including dual immunotherapy and chemotherapy combination regimens, in advanced non–small-cell lung cancer (NSCLC); Identify strategies for tailoring dual immunotherapy and chemotherapy combination regimens for individualized frontline treatment of advanced NSCLC; and Outline practical approaches to improve quality of life in patients with advanced NSCLC on frontline dual immunotherapy and chemotherapy combination regimens.

Please visit answersincme.com/FKQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Dr. Anne O’Donnell, an expert in pulmonology, discusses the role of diagnostic imaging in the diagnosis of non–cystic fibrosis bronchiectasis (NCFB). Upon completion of this activity, participants should be better able to: Recognize the clinical impact of early diagnosis of non–cystic fibrosis bronchiectasis (NCFB); Identify NCFB based on diagnostic imaging; and Describe the clinical profiles of novel and emerging neutrophil-targeted therapies for NCFB.

Please visit answersincme.com/TVT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in endocrinology discusses how to optimize the use of novel non-steroidal mineralocorticoid receptor antagonists (MRAs) for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.

Please visit answersincme.com/RYP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses personalized treatment strategies for chronic obstructive pulmonary disease (COPD) management, specifically the use of triple inhaler therapies. Upon completion of this activity, participants should be better able to: Identify patients with COPD who are inadequately controlled with dual bronchodilation; Describe the clinical profiles of available triple inhaler therapies for the treatment of patients with moderate to severe COPD; and Outline evidence-based, patient-centric strategies to optimize outcomes for patients with moderate to severe COPD.

Please visit answersincme.com/PRH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses the guideline-recommended approach to incorporating non-steroidal mineralocorticoid receptor antagonists (MRAs) into the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Describe the role of non-steroidal MRAs in the treatment of patients with CKD and T2D; Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Review the latest guideline updates informing the use of novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.

Please visit answersincme.com/YWV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses treatment of children with uncontrolled asthma using biologic therapies. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment intensification with a biologic; Review the clinical profiles of current biologics used in the management of moderate-to-severe asthma in children; and Outline evidence-based strategies to optimize outcomes for pediatric patients with moderate-to-severe asthma who require biologics.